About us
- >
- About us >
- Information >
- Announcement
2025-10-22
Energenesis Biomedical Announces IND Submission to the U.S. FDA for Phase II Clinical Trial of ENERGI-F703EB Cream
Energenesis Biomedical Co., Ltd. has received notification from its contract research organization (CRO) that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for conducting a Phase II clinical trial of the investigational new drug ENERGI-F703EB, a topical cream developed for the treatment of Epidermolysis Bullosa (EB), a rare genetic skin disorder characterized by fragile skin and chronic blistering.
The planned clinical development includes Phase II and subsequent clinical trials. Actual timelines will be adjusted according to regulatory review and clinical progress.